The cancer immunotherapy space has no lack of PD-1/L1 immune checkpoint inhibitors, from the Opdivo (nivolumab) and Keytruda (pembrolizumab) juggernauts to more niche players like Sanofi US and Regeneron Pharmaceuticals, Inc.’s Libtayo (cemiplimab), but the lineup nonetheless is poised to expand even more in 2021. One just got approved by the US FDA, three novel PD-1/L1 inhibitors are under review, and more are advancing through pivotal trials.
FDA is in middle of a fire and ice month for the category, having just cleared GlaxoSmithKline plc’s Jemperli...






